Louisbourg Investments Inc. Has $7.89 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Louisbourg Investments Inc. grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,765 shares of the medical instruments supplier’s stock after purchasing an additional 3,855 shares during the period. Becton, Dickinson and Company comprises 1.9% of Louisbourg Investments Inc.’s holdings, making the stock its 12th largest holding. Louisbourg Investments Inc.’s holdings in Becton, Dickinson and Company were worth $7,887,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth $33,000. Tompkins Financial Corp grew its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank acquired a new position in Becton, Dickinson and Company in the third quarter valued at about $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $229.50 on Wednesday. The stock has a market cap of $66.56 billion, a PE ratio of 38.12, a PEG ratio of 1.65 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The business has a 50-day simple moving average of $232.36 and a two-hundred day simple moving average of $233.94. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Analysts anticipate that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.81%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the sale, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the transaction, the executive vice president now owns 16,201 shares in the company, valued at $3,807,235. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,844 shares of company stock valued at $2,210,716 over the last quarter. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on BDX shares. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.